HEALTH OF WOMAN. 2015.8(104):19–24 

The effectiveness of micronized progesterone sublingual and vaginal forms combined use of in the treatment of preterm labor 

Golyanovskyy O. V., Rubinshtein A. M., Bachinska M. A.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev 

The article presents current data about the peculiarities of etiology and pathogenesis, clinics and treatment of preterm labor. The results of the clinical studies of the effectiveness of micronized progesterone sublingual and vaginal forms combined therapy of preterm labor threat at 22–30 weeks were described. 

Key words: the threat preterm labor, a sublingual form of micronized progesterone (Luteina), vaginal form of micronized progesterone, oil progesterone. 

REFERENCES

1. Інструкція застосування препарату Лютеїна.

2. Каминский ВВ, Жук СИ. 2008. Токолитическая терапия: новые возможности. Жіночий лікар 6:3.

3. Майоров МВ. 2004. Гестагены в акушерско-гинекологической практике. Провизор 7:26–29.

4. Наказ МОЗ України від 31.12.2004 року № 676 «Про затвердження клінічних протоколів з акушерської та гінекологічної допомоги» розділ «Передчасні пологи» та зміни до нього № 624 від 03.11.2008 р.

5. Goldenberg RL, Iams JD, Mercer BM et al. 1998. The preterm prediction study: the value of new vs. standard risk factors in predicting early and all spontaneous preterm births. Am J Public Health 88:233–238. http://dx.doi.org/10.2105/AJPH.88.2.233; PMid:9491013 PMCid:PMC1508185

6. Goldenberg RL, Culhane JF, Iams JD, Romero R. 2008. Epidemiology and causes of preterm birth, The Lancet. 371(9606):75–84. http://dx.doi.org/10.1016/S0140-6736(08)60074-4

7. Management of preterm labor. Practice Bulletin No. 127. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119:1308–13. http://dx.doi.org/10.1097/AOG.0b013e31825af2f0; PMid:22617615

8. Maternal mortality in 2005: estimates developed by WHO, UNICEF, UNFPA, and The World Bank. Geneva: World Health Organization. 2007.

9. Romero R, Nicolaides K, Conde-Agudelo A et al. 2012. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am. J. Obstet. Gynecol. 206;2:124.e1–19. http://dx.doi.org/10.1016/j.ajog.2011.12.003; PMid:22284156 PMCid:PMC3437773

10. Saigal S, Hoult LA, Streiner DL et al. 2000. School difficulties at adolescence in a regional cohort of children who were extremely low birth weight. Pediatrics. 105;2:325–331. http://dx.doi.org/10.1542/peds.105.2.325

11. Tyson JE, Prarikh NA, Langer J et al. 2008. Intensive care for extreme prematurity: moving beyond gestational age. N. Engl. J. Med. 358;16:1672–1681. http://dx.doi.org/10.1056/NEJMoa073059; PMid:18420500 PMCid:PMC2597069

12. Use of progesterone to reduce preterm birth/American College of Obstetricians and Gynecologists. Obstet Gynecol. 112: 963–5. 2008. PMid:18827143

13. Hassan SS, Romero R, Vidyadhari D et al. 2011, July. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics & Gynecology. 38;Is.1:18–31.